17-GMB-APA-GA is a synthetic analog of geldanamycin engineered with a maleimido moiety, enabling its use in the development of immunoconjugates. While its primary application has been in targeted cancer therapies, its potential in neuroscience lies in its ability to selectively bind HSP90, a chaperone protein implicated in neurodegenerative disease pathways. By facilitating the targeted delivery of HSP90 inhibitors to specific cell types, 17-GMB-APA-GA may offer a novel strategy for modulating proteostasis in neural tissues. This targeted approach could enhance the clearance of misfolded proteins such as alpha-synuclein and tau, which are central to the pathology of Parkinson's and Alzheimer's diseases. Although further research is needed to validate its efficacy in neural models, 17-GMB-APA-GA represents a promising tool for precision medicine in neurodegeneration.